ImmunoGenesis has dosed the first subject in a Phase I/II trial evaluating IMGS-101 (evofosfamide) in combination with checkpoint inhibitors balstilimab and zalifrelimab at MD Anderson Cancer Center.
Phase II study evaluates innovative combination of AgenT-797 (iNKT cell therapy), botensilimab (CTLA-4 inhibitor), and balstilimab (PD-1 inhibitor) in PD-1 refractory gastroesophageal cancer patients.
Agenus will showcase interim data from a Phase 2 study combining BOT/BAL with iNKT cell therapy AgenT-797 in refractory gastric cancer patients at the AACR IO Annual Meeting.
Agenus's botensilimab/balstilimab combination therapy demonstrated strong efficacy in colorectal cancer treatment, achieving a 65% pathologic response rate and 38% complete response rate across all patients.